| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/20/2011 | WO2011008636A1 3-oxy-hydromorphone derivatives |
| 01/20/2011 | WO2011008585A2 Methods and compositions for protecting and treating neuroinjury |
| 01/20/2011 | WO2011008572A2 5-ht3 receptor modulators, methods of making, and use thereof |
| 01/20/2011 | WO2011008548A1 Vaccines and compositions against streptococcus pneumoniae |
| 01/20/2011 | WO2011008543A2 Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
| 01/20/2011 | WO2011008490A2 Combination therapies for the treatment of obesity |
| 01/20/2011 | WO2011008487A1 Pyrimidinones as pi3k inhibitors |
| 01/20/2011 | WO2011008475A1 Optionally substituted 2-(arylmethyl, aryloxy or arylthio) -n- pyridin-2 -yl-aryl acetamide or 2, 2-bis (aryl) -n-pyridin-2-yl acetamide compounds as medicaments for the treatment of eye diseases |
| 01/20/2011 | WO2011008347A1 Treating patients with intravenous ibuprofen |
| 01/20/2011 | WO2011008324A1 Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
| 01/20/2011 | WO2011008305A1 Rna antagonists targeting gli2 for the treatment of leukemia |
| 01/20/2011 | WO2011008302A1 Certain chemical entities, compositions and methods |
| 01/20/2011 | WO2011008298A2 Novel axomadol dosage forms |
| 01/20/2011 | WO2011008230A2 Rapamycin derivatives and ethers of n-propanolamines and uses related to infection |
| 01/20/2011 | WO2011008193A1 Fusidic acid dosing regimens for treatment of bacterial infections |
| 01/20/2011 | WO2011008183A1 Trimetazidine dihydrochloride-containing medication in the form of an extended-release matrix tablet (variants) and methods for preparing same (variants) |
| 01/20/2011 | WO2011008172A1 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt |
| 01/20/2011 | WO2011008132A1 Low molecular weight pharmacological activity modulators |
| 01/20/2011 | WO2011008110A1 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase |
| 01/20/2011 | WO2011008087A1 Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit |
| 01/20/2011 | WO2011008086A1 Mixture of non-digestible oligosaccharides for stimulating the immune system |
| 01/20/2011 | WO2011008054A2 Butyric acid salt of n,n-dimethyl imidocarbon imidic diamide, method of preparing same, and pharmaceutical compositions and combinations containing same |
| 01/20/2011 | WO2011008052A2 Composition for the prevention or treatment of bone diseases comprising colforsin daropate |
| 01/20/2011 | WO2011008001A2 Antihypertensive composition containing a ginsenoside-enriched fraction |
| 01/20/2011 | WO2011007961A2 Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes |
| 01/20/2011 | WO2011007899A1 Glycine transporter inhibitors |
| 01/20/2011 | WO2011007895A1 Process for producing crystals of polymorphic 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecaboxylic acid by poor-solvent addition method |
| 01/20/2011 | WO2011007893A1 Eye drop with difluprednate for macular edema treatment |
| 01/20/2011 | WO2011007882A1 Insulin-producing cell inducer, glucose intake enhancer, and therapeutic agent for diabetes or diabetes complications |
| 01/20/2011 | WO2011007876A1 Nucleic acid molecule capable of binding to hmgb1, and use thereof |
| 01/20/2011 | WO2011007870A1 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof |
| 01/20/2011 | WO2011007866A1 Agent for treatment of myotonic dystrophy |
| 01/20/2011 | WO2011007865A1 Agent for inhibiting increase in postprandial blood insulin level |
| 01/20/2011 | WO2011007864A1 Inhibitor of blood gip level elevation |
| 01/20/2011 | WO2011007863A1 Inhibitor of blood triglyceride level elevation |
| 01/20/2011 | WO2011007859A1 Dna fragment and pharmaceutical composition |
| 01/20/2011 | WO2011007856A1 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer |
| 01/20/2011 | WO2011007838A1 Benzimidazole-based injection solution |
| 01/20/2011 | WO2011007819A1 Pharmaceutical product containing lactam or benzene sulfonamide compound |
| 01/20/2011 | WO2011007807A1 Method for manufacturing spilanthol and intermediate manufacturing product therefor |
| 01/20/2011 | WO2011007801A1 Anti-cancer agent, method for inducing apoptosis of cancer cells, and method for screening for anti-cancer agent |
| 01/20/2011 | WO2011007795A1 Composition for inhibiting the expression of target gene |
| 01/20/2011 | WO2011007756A1 Heterocyclic compound and use thereof |
| 01/20/2011 | WO2011007722A1 3-substituted-2-furancarboxylic acid hydrazide derivative and pharmaceutically acceptable salt thereof |
| 01/20/2011 | WO2011007633A1 Crystals of pyrroloquinolinequinone sodium salts |
| 01/20/2011 | WO2011007552A1 Bad breath-removing agent |
| 01/20/2011 | WO2011007551A1 Sugar alcohol-containing antibacterial agent for inhibiting proliferation of periodontal disease-causing bacteria |
| 01/20/2011 | WO2011007324A1 Pyridin-4-yl derivatives |
| 01/20/2011 | WO2011007320A1 Humic substances and therapeutic uses thereof |
| 01/20/2011 | WO2011007247A1 Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof |
| 01/20/2011 | WO2011007208A1 Compounds and methods for the treatment of cancer |
| 01/20/2011 | WO2011007135A1 Use of pro-inflammatory compounds for promoting bone formation |
| 01/20/2011 | WO2011007102A1 Use of at least one omega-3 fatty acid and of at least one polyphenol for the endogenous synthesis of eicosapentanoic acid and docosahexanoic acid |
| 01/20/2011 | WO2011007091A1 Derivatives of 5,6-bisaryl-2-pyridine-carboxamide, preparation thereof, and therapeutic use thereof as urotensin-ii receptor antagonists |
| 01/20/2011 | WO2011007090A1 Derivatives of 5,6-bisaryl-2-pyrimidine-carboxamide, preparation thereof, and therapeutic use thereof as urotensin-ii receptor antagonists |
| 01/20/2011 | WO2011006988A1 Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors |
| 01/20/2011 | WO2011006984A1 Amino derivatives of dihydro-1,3,5-triazine used in the treatment of ischemia and/or reperfusion related diseases |
| 01/20/2011 | WO2011006983A1 Amino derivatives of dihydro-1,3,5-triazine for treating oxidative stress |
| 01/20/2011 | WO2011006980A1 Method for inhibiting the maturation of dendritic cells |
| 01/20/2011 | WO2011006960A1 Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction |
| 01/20/2011 | WO2011006938A1 Use of proanthocyanidins for production of an antiadhesive preparation |
| 01/20/2011 | WO2011006936A1 Tricyclic indole-derived spiro derivatives as crth2 modulators |
| 01/20/2011 | WO2011006935A2 Tetrazole derivatives |
| 01/20/2011 | WO2011006910A1 Imidazole derivatives as mglur5 antagonists |
| 01/20/2011 | WO2011006908A2 Metal complexes having dual histone deacetylase inhibitory and dna-binding activity |
| 01/20/2011 | WO2011006903A1 Substituted triazole and imidazole derivatives as gamma secretase modulators |
| 01/20/2011 | WO2011006803A1 3-0x0-2, 3, -dihydro-lh-isoindole-4-carboxamides with selective parp-1 inhibition |
| 01/20/2011 | WO2011006794A1 3-oxo-2, 3-dihydro-lh-isoindole-4-carboxamides as parp inhibitors |
| 01/20/2011 | WO2011006670A1 Separating layers for pharmaceutical preparations to prevent interactions between medicinal drugs and pharmaceutical-technological adjuvants |
| 01/20/2011 | WO2011006653A1 An agent for restoring lost memory on the basis of n,n'-substituted 3,7-diazabicyclo[3.3.1] nonanes |
| 01/20/2011 | WO2011006638A1 Process for the synthesis of paliperidone |
| 01/20/2011 | WO2011006573A1 Combination of a sodium-proton exchanger inhibitor and of a dihydro-1,3,5-triazine amine derivative |
| 01/20/2011 | WO2011006569A1 Heterocyclic compounds as autotaxin inhibitors |
| 01/20/2011 | WO2011006567A1 Aminopyridine derivatives for treating tumors and inflammatory diseases |
| 01/20/2011 | WO2011006536A1 Pyridyl-substituted isoquinoline derivatives with activity againstmycobacteriaand especially myobacterium tuberculosis |
| 01/20/2011 | WO2011006387A1 Process for preparing agomelatine, crystals of agomelatine and preparing process thereof |
| 01/20/2011 | WO2011006355A1 Compounds as hypoxia mimetics, and compositions, and uses thereof |
| 01/20/2011 | WO2011006263A1 Antibacterial oral composition |
| 01/20/2011 | WO2011006237A1 2,3-fluorinated glycosides as neuraminidase inhibitors and their use as anti-virals |
| 01/20/2011 | WO2011006208A1 Anti -influenza agents |
| 01/20/2011 | WO2010138600A3 Pharmaceutical compositions for the treatment of pain |
| 01/20/2011 | WO2010136474A3 Substituted aminobutyric derivatives as neprilysin inhibitors |
| 01/20/2011 | WO2010133359A3 The improvement of gastrointestinal health, immunity and performance by dietary intervention |
| 01/20/2011 | WO2010132839A3 Aminoglycoside dosing regimens |
| 01/20/2011 | WO2010132777A3 Treatment of urinary tract infections with antibacterial aminoglycoside compounds |
| 01/20/2011 | WO2010129918A8 Triptolide prodrugs |
| 01/20/2011 | WO2010123599A3 Anti-bacterial compositions and methods including targeting virulence factors of staphylococcus aureus |
| 01/20/2011 | WO2010120400A3 Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors |
| 01/20/2011 | WO2010120370A3 Gamma-amino-butyric acid derivatives as gabab receptor ligands |
| 01/20/2011 | WO2010116385A3 Pharmaceutical compositions for alleviating unpleasant taste |
| 01/20/2011 | WO2010114319A9 Composition for bone regeneration |
| 01/20/2011 | WO2010111503A3 RNA INTERFERENCE MEDIATED INHIBITION OF THE HIGH AFFINITY IGE RECEPTOR ALPHA CHAIN (FCεRLα) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
| 01/20/2011 | WO2010109480A3 Processes for preparation of indiplon and intermediates thereof |
| 01/20/2011 | WO2010105995A3 Zoo-technical drug delivery device |
| 01/20/2011 | WO2010102286A3 Proteasome inhibitors having chymotrypsin-like activity |
| 01/20/2011 | WO2010090502A3 External use composition containing cholecalciferol or its derivative for treating skin disorders |
| 01/20/2011 | WO2010062656A3 Deuterated 2-propylpentanoic acid compounds |
| 01/20/2011 | WO2010061269A3 Improving cancer therapy by docetaxel and granulocyte colony-stimulating factor (g-csf) |
| 01/20/2011 | WO2010032006A3 Treatment of adrenal insufficiency |
| 01/20/2011 | WO2010003475A8 Novel pyrrolidone derivatives for use as metap-2 inhibitors |